Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
RELATED PRODUCTS
-
PYROPHOSPHATE
PYROPHOSPHATEIt is indicated for performing bone scintigraphy, detection of cardiac pathologies and "in vivo" and "in vitro" marking of erythrocytes. 1) In vivo, in vitro or in vivo/in vitro marking of red blood cells to... -
IODOSOL 123I (R&D)
IODOSOL 123I (R&D)Sodium iodide (123I) solution is indicated as a diagnostic agent to evaluate thyroid function and/or morphology by scintigraphy and radioactive iodine uptake test. -
PARTITION FLASK
PARTITION FLASKVial containing a mixture of solvents to carry out a chromatographic separation ... -
AV45 (R+D)
AV45 (R+D)It is indicated for estimating the density of β-amyloid neuritic plaque in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive... -
131I MIBG BACON (R&D)
131I MIBG BACON (R&D)It is indicated for the diagnosis and location of neuroendocrine tumors, pheochromocytoma, medullary thyroid cancer, primary neuroblastomas and their metastases, paragangliomas and thymomas...

